Journal of Neurology

, Volume 263, Issue 5, pp 981–990 | Cite as

Clinical features and prognostic factors of spinal cord sarcoidosis: a multicenter observational study of 20 BIOPSY-PROVEN patients

  • Cécile-Audrey Durel
  • Romain Marignier
  • Delphine Maucort-Boulch
  • Jean Iwaz
  • Emilie Berthoux
  • Marc Ruivard
  • Marc André
  • Guillaume Le Guenno
  • Laurent Pérard
  • Jean-François Dufour
  • Alin Turcu
  • Jean-Christophe Antoine
  • Jean-Philippe Camdessanche
  • Thierry Delboy
  • Pascal Sève
Original Communication


Sarcoidosis of the spinal cord is a rare disease. The aims of this study are to describe the features of spinal cord sarcoidosis (SCS) and identify prognostic markers. We analyzed 20 patients over a 20-year period in 8 French hospitals. There were 12 men (60 %), mostly Caucasian (75 %). The median ages at diagnosis of sarcoidosis and myelitis were 34.5 and 37 years, respectively. SCS revealed sarcoidosis in 12 patients (60 %). Eleven patients presented with motor deficit (55 %) and 9 had sphincter dysfunction (45 %). The median initial Edmus Grading Scale (EGS) score was 2.5. The cerebrospinal fluid (CSF) showed elevated protein level (median: 1.00 g/L, interquartile range (IQR) 0.72–1.97), low glucose level (median 2.84 mmol/L, IQR 1.42–3.45), and elevated white cell count (median 22/mm3, IQR 6–45). The cervical and thoracic cords were most often affected (90 %). All patients received steroids and an immunosuppressive drug was added in 10 cases (50 %). After a mean follow-up of 52.1 months (range 8–43), 18 patients had partial response (90 %), 7 displayed functional impairment (35 %), and the median final EGS score was 1. Six patients experienced relapse (30 %). There was an association between the initial and the final EGS scores (p = 0.006). High CSF protein level showed a trend toward an association with relapse (p = 0.076). The spinal cord lesion was often the presenting feature of sarcoidosis. Most patients experienced clinical improvement with corticosteroids and/or immunosuppressive treatment. The long-term functional prognosis was correlated with the initial severity.


Sarcoidosis Neurosarcoidosis Spinal cord sarcoidosis Myelopathy Morbidity Sequelae 


Compliance with ethical standard

Conflicts of interest

No financial or personal relationships could potentially influence the study and its conclusions.

Ethical standard

According to the French law, this retrospective observational study did not require a Local Institutional Review Board approval


  1. 1.
    Iannuzzi MC, Rybicki BA, Teirstein AS (2007) Sarcoidosis. N Engl J Med 357(21):2153–2165CrossRefPubMedGoogle Scholar
  2. 2.
    Lower EE, Weiss KL (2008) Neurosarcoidosis. Clin Chest Med 29(3):475–492CrossRefPubMedGoogle Scholar
  3. 3.
    Chapelon C, Ziza JM, Piette JC, Levy Y, Raguin G, Wechsler B et al (1990) Neurosarcoidosis: signs, course and treatment in 35 confirmed cases. Medicine (Baltimore) 69(5):261–276CrossRefGoogle Scholar
  4. 4.
    Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF et al (1999) Central nervous system sarcoidosis—diagnosis and management. QJM Mon J Assoc Physicians 92(2):103–117CrossRefGoogle Scholar
  5. 5.
    Sharma OP (1997) Neurosarcoidosis: a personal perspective based on the study of 37 patients. Chest 112(1):220–228CrossRefPubMedGoogle Scholar
  6. 6.
    Stern BJ, Krumholz A, Johns C, Scott P, Nissim J (1985) Sarcoidosis and its neurological manifestations. Arch Neurol 42(9):909–917CrossRefPubMedGoogle Scholar
  7. 7.
    James DG, Sharma OP (1967) Neurosarcoidosis. Proc R Soc Med 60(11 Part 1):1169–1170PubMedPubMedCentralGoogle Scholar
  8. 8.
    Scott TF, Yandora K, Valeri A, Chieffe C, Schramke C (2007) Aggressive therapy for neurosarcoidosis: long-term follow-up of 48 treated patients. Arch Neurol 64(5):691–696CrossRefPubMedGoogle Scholar
  9. 9.
    Bogousslavsky J, Hungerbühler JP, Regli F, Graf HJ (1982) Subacute myelopathy as the presenting manifestation of sarcoidosis. Acta Neurochir (Wien) 65(3–4):193–197CrossRefGoogle Scholar
  10. 10.
    Cohen-Aubart F, Galanaud D, Grabli D, Haroche J, Amoura Z, Chapelon-Abric C et al (2010) Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study. Medicine (Baltimore) 89(2):133–140CrossRefGoogle Scholar
  11. 11.
    Varron L, Broussolle C, Candessanche JP, Marignier R, Rousset H, Ninet J et al (2009) Spinal cord sarcoidosis: report of seven cases. Eur J Neurol Off J Eur Fed Neurol Soc 16(3):289–296Google Scholar
  12. 12.
    Bradley DA, Lower EE, Baughman RP (2006) Diagnosis and management of spinal cord sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG World Assoc Sarcoidosis Granulomatous Disord 23(1):58–65Google Scholar
  13. 13.
    Judson MA, Costabel U, Drent M, Wells A, Maier L, Koth L et al (2014) The WASOG Sarcoidosis Organ Assessment Instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG World Assoc Sarcoidosis Granulomatous Disord 31(1):19–27Google Scholar
  14. 14.
    Baughman RP, Lower EE, du Bois RM (2003) Sarcoidosis. Lancet Lond Engl 361(9363):1111–1118CrossRefGoogle Scholar
  15. 15.
    Newman LS, Rose CS, Maier LA (1997) Sarcoidosis. N Engl J Med 336(17):1224–1234CrossRefPubMedGoogle Scholar
  16. 16.
    Sakushima K, Yabe I, Nakano F, Yoshida K, Tajima Y, Houzen H et al (2011) Clinical features of spinal cord sarcoidosis: analysis of 17 neurosarcoidosis patients. J Neurol 258(12):2163–2167CrossRefPubMedGoogle Scholar
  17. 17.
    Ota K, Tsunemi T, Saito K, Yamanami F, Watanabe M, Irioka T et al (2009) 18F-FDG PET successfully detects spinal cord sarcoidosis. J Neurol 256(11):1943–1946CrossRefPubMedGoogle Scholar
  18. 18.
    Saleh S, Saw C, Marzouk K, Sharma O (2006) Sarcoidosis of the spinal cord: literature review and report of eight cases. J Natl Med Assoc 98(6):965–976PubMedPubMedCentralGoogle Scholar
  19. 19.
    Sohn M, Culver DA, Judson MA, Scott TF, Tavee J, Nozaki K (2014) Spinal cord neurosarcoidosis. Am J Med Sci 347(3):195–198CrossRefPubMedGoogle Scholar
  20. 20.
    Christoforidis GA, Spickler EM, Recio MV, Mehta BM (1999) MR of CNS sarcoidosis: correlation of imaging features to clinical symptoms and response to treatment. AJNR Am J Neuroradiol 20(4):655–669PubMedGoogle Scholar
  21. 21.
    Rahmi A, Deshayes E, Maucort-Boulch D, Varron L, Grange JD, Kodjikian L et al (2012) Intraocular sarcoidosis: association of clinical characteristics of uveitis with findings from 18F-labelled fluorodeoxyglucose positron emission tomography. Br J Ophthalmol 96(1):99–103CrossRefPubMedGoogle Scholar
  22. 22.
    Spencer TS, Campellone JV, Maldonado I, Huang N, Usmani Q, Reginato AJ (2005) Clinical and magnetic resonance imaging manifestations of neurosarcoidosis. Semin Arthritis Rheum 34(4):649–661CrossRefPubMedGoogle Scholar
  23. 23.
    MacLean HJ, Abdoli M (2015) Neurosarcoidosis as an MS Mimic: the trials and tribulations of making a diagnosis. Mult Scler Relat Disord 4(5):414–429CrossRefPubMedGoogle Scholar
  24. 24.
    Kobayashi S, Nakata W, Sugimoto H (2013) Spinal magnetic resonance imaging manifestations at neurological onset in Japanese patients with spinal cord sarcoidosis. Intern Med Tokyo Jpn. 52(18):2041–2050CrossRefGoogle Scholar
  25. 25.
    Lexa FJ, Grossman RI (1994) MR of sarcoidosis in the head and spine: spectrum of manifestations and radiographic response to steroid therapy. AJNR Am J Neuroradiol 15(5):973–982PubMedGoogle Scholar
  26. 26.
    Nesbit GM, Miller GM, Baker HL, Ebersold MJ, Scheithauer BW (1989) Spinal cord sarcoidosis: a new finding at MR imaging with Gd-DTPA enhancement. Radiology 173(3):839–843CrossRefPubMedGoogle Scholar
  27. 27.
    Koike H, Misu K, Yasui K, Kameyama T, Ando T, Yanagi T et al (2000) Differential response to corticosteroid therapy of MRI findings and clinical manifestations in spinal cord sarcoidosis. J Neurol 247(7):544–549CrossRefPubMedGoogle Scholar
  28. 28.
    Dumas JL, Valeyre D, Chapelon-Abric C, Belin C, Piette JC, Tandjaoui-Lambiotte H et al (2000) Central nervous system sarcoidosis: follow-up at MR imaging during steroid therapy. Radiology 214(2):411–420CrossRefPubMedGoogle Scholar
  29. 29.
    Bridel C, Courvoisier DS, Vuilleumier N, Lalive PH (2015) Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of neurosarcoidosis. J Neuroimmunol 285:1–3CrossRefPubMedGoogle Scholar
  30. 30.
    Hebel R, Dubaniewicz-Wybieralska M, Dubaniewicz A (2015) Overview of neurosarcoidosis: recent advances. J Neurol 262(2):258–267CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Perel P, Edwards P, Shakur H, Roberts I (2008) Use of the Oxford Handicap Scale at hospital discharge to predict Glasgow Outcome Scale at 6 months in patients with traumatic brain injury. BMC Med Res Methodol 8:72CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Nozaki K, Judson MA (2013) Neurosarcoidosis. Curr Treat Options Neurol 15(4):492–504CrossRefPubMedGoogle Scholar
  33. 33.
    Bagnato F, Stern BJ (2015) Neurosarcoidosis: diagnosis, therapy and biomarkers. Expert Rev Neurother 15(5):533–548CrossRefPubMedGoogle Scholar
  34. 34.
    Agbogu BN, Stern BJ, Sewell C, Yang G (1995) Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol 52(9):875–879CrossRefPubMedGoogle Scholar
  35. 35.
    Riancho-Zarrabeitia L, Delgado-Alvarado M, Riancho J, Oterino A, Sedano MJ, Rueda-Gotor J et al (2014) Anti-TNF-α therapy in the management of severe neurosarcoidosis: a report of five cases from a single centre and literature review. Clin Exp Rheumatol 32(2):275–284PubMedGoogle Scholar
  36. 36.
    Pritchard C, Nadarajah K (2004) Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis 63(3):318–320CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Sollberger M, Fluri F, Baumann T, Sonnet S, Tamm M, Steck AJ et al (2004) Successful treatment of steroid-refractory neurosarcoidosis with infliximab. J Neurol 251(6):760–761CrossRefPubMedGoogle Scholar
  38. 38.
    Pettersen JA, Zochodne DW, Bell RB, Martin L, Hill MD (2002) Refractory neurosarcoidosis responding to infliximab. Neurology 59(10):1660–1661CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Cécile-Audrey Durel
    • 1
    • 2
  • Romain Marignier
    • 3
  • Delphine Maucort-Boulch
    • 2
    • 4
    • 5
  • Jean Iwaz
    • 2
    • 4
    • 5
  • Emilie Berthoux
    • 6
  • Marc Ruivard
    • 7
  • Marc André
    • 8
  • Guillaume Le Guenno
    • 7
  • Laurent Pérard
    • 9
  • Jean-François Dufour
    • 10
  • Alin Turcu
    • 11
  • Jean-Christophe Antoine
    • 12
  • Jean-Philippe Camdessanche
    • 12
  • Thierry Delboy
    • 13
  • Pascal Sève
    • 1
    • 2
  1. 1.Département de Médicine Interne, Hôpital de la Croix-RousseHospices Civils de LyonLyonFrance
  2. 2.Université de Lyon, Université Lyon 1VilleurbanneFrance
  3. 3.Département de Neurologie, Hôpital Pierre WertheimerHospices Civils de LyonBronFrance
  4. 4.Service de BiostatistiqueHospices Civils de LyonLyonFrance
  5. 5.CNRS UMR 555, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique SantéVilleurbanneFrance
  6. 6.Département de Médicine InterneCH Saint Luc Saint JosephLyonFrance
  7. 7.Département de Médecine InterneCHU de Clermont-Ferrand, CHU EstaingClermont-FerrandFrance
  8. 8.Service de Médecine InterneCHU Clermont-Ferrand, Hôpital Gabriel MontpiedClermont-FerrandFrance
  9. 9.Département de Médecine Interne, Hôpital Edouard HerriotHospices Civils de LyonLyonFrance
  10. 10.Département de Médecine InterneCentre hospitalier FleyriatBourg-en-BresseFrance
  11. 11.Département de Médecine Interne et Maladies SystémiquesCHU DijonDijonFrance
  12. 12.Département de NeurologieCHU de Saint-Etienne, Hôpital NordSaint Etienne Cedex 022France
  13. 13.Département de Médecine Interne, CH MontluçonMontluçonFrance

Personalised recommendations